



NT157

Cat. No.:	OB0225WX-2738
Appearance:	Solid
Purity:	≥98%
Identity:	Confirmed by NMR, and HPLC.
Size:	2 mg; 5 mg; 25 mg; 100 mg; 1 g

This product is for research use only and is not intended for diagnostic use.

Product Overview

Description	NT157 functions as a selective inhibitor of insulin receptor substrates (IRS-1/2), capable of disrupting STAT3 and IGF-1R signaling pathways within both cancer cells and the tumor microenvironment.
Synonym	1384426-12-3; (E)-3-(3-Bromo-4,5-dihydroxyphenyl)-N-(3,4,5-trihydroxybenzyl)prop-2-enethioamide; NT-157; (E)-3-(3-bromo-4,5-dihydroxyphenyl)-N-[(3,4,5-trihydroxyphenyl)methyl]prop-2-enethioamide; 2-Propenethioamide, 3-(3-bromo-4,5-dihydroxyphenyl)-N-[(3,4,5-trihydroxyphenyl)methyl]-, (2E)-
CAS No.	1384426-12-3
Compound CID	135398520
Formula	C ₁₆ H ₁₄ BrNO ₅ S
Formula Weight	412.26

Specification

IUPAC Name	(E)-3-(3-Bromo-4,5-dihydroxyphenyl)-N-[(3,4,5-trihydroxyphenyl)methyl]prop-2-enethioamide
InChI	InChI=1S/C16H14BrNO5S/c17-10-3-8(4-11(19)15(10)22)1-2-14(24)18-7-9-5-12(20)16(23)13(21)6-9/h1-6,19-23H,7H2,(H,18,24)/b2-1+
InChI Key	NIPUPOUEGOSAAO-OWOJBTEDSA-N
SMILES string	C1=C(C=C(C(=C1O)O)O)CNC(=S)/C=C/C2=CC(=C(C(=C2)Br)O)O
Stability	3 years in powder form.



Storage	Storage at -20°C.
Applications	NT157 is used in oncology and signal transduction research as a potent dual inhibitor of IRS-1/2 and STAT3 to investigate the simultaneous disruption of insulin-like growth factor signaling and transcription factor activity.

Library Information

Target	IGF-1R
Receptor	IGF-1R
Pathways	Protein tyrosine kinase
Plate Number	L6700-10
Empty Location	a1-h1; a12-h12
Container	96-well plate
Formulation	10mM DMSO
DMSO Max Solubility	82 mg/mL; 198.9 mM
Ethanol Max Solubility	82 mg/mL
ALogP	3.721
HBA_Count	0
HBD_Count	6
Rotatable Bond	5